Micromet’s Cancer Missiles Lure Boehringer, Sanofi (Update2)
From Businessweek (June 14, 2010, 4:25 PM EDT):
"What Micromet has developed is a way to activate T-cells, the elite troops of the immune system, to attack malignancies, including a rare leukemia that strikes children. It has signed partnerships with five of Europe’s largest drug companies: Bayer AG, Sanofi-Aventis SA, AstraZeneca Plc, Merck KGaA and Boehringer Ingelheim GmbH."
...
"The disease blinatumomab is designed to treat, acute lymphocytic leukemia or ALL, isn’t common, but it is a high priority for some doctors. One reason is that two-thirds of the 5,400 new cases in the U.S. each year are children, many of whom only survive with painful chemotherapy that continues for years."
...
No comments:
Post a Comment